NSCLC patients with EGFR mutations exhibit high triggering receptor expressed on myeloid cells 2 (TREM2)-positive (+) TAM infiltrations with unique NSCLC molecular features and advanced cancer progression (21). The gene discussed is TREM2; the disease is non-small cell lung carcinoma.